Furthermore, a decreased risk of cancer has been reported in patients with FXS (Schultz-Pedersen et al, 2001), a decreased expression of the Wnt7A oncogene was detected in patients with FXS (Rosales-Reynoso et al, 2010) and a case study showed that a patient with FXS had an unusual decrease of tumour brain invasiveness (Kalkunte et al, 2007). This evidence concerns the gene WNT7A and fragile X syndrome.